PT2400960E - Metabolitos análogos à ceramida - Google Patents

Metabolitos análogos à ceramida Download PDF

Info

Publication number
PT2400960E
PT2400960E PT107051609T PT10705160T PT2400960E PT 2400960 E PT2400960 E PT 2400960E PT 107051609 T PT107051609 T PT 107051609T PT 10705160 T PT10705160 T PT 10705160T PT 2400960 E PT2400960 E PT 2400960E
Authority
PT
Portugal
Prior art keywords
compound
iii
compounds
alkyl chain
pharmaceutical composition
Prior art date
Application number
PT107051609T
Other languages
English (en)
Portuguese (pt)
Inventor
Guido Jordine
Markus Zollinger
Claudia Sayer
Volker Brinkmann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT2400960E publication Critical patent/PT2400960E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT107051609T 2009-02-24 2010-02-23 Metabolitos análogos à ceramida PT2400960E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09153550 2009-02-24

Publications (1)

Publication Number Publication Date
PT2400960E true PT2400960E (pt) 2013-06-28

Family

ID=40447014

Family Applications (1)

Application Number Title Priority Date Filing Date
PT107051609T PT2400960E (pt) 2009-02-24 2010-02-23 Metabolitos análogos à ceramida

Country Status (14)

Country Link
US (1) US8673982B2 (cg-RX-API-DMAC7.html)
EP (1) EP2400960B1 (cg-RX-API-DMAC7.html)
JP (1) JP2012518671A (cg-RX-API-DMAC7.html)
KR (1) KR20110126631A (cg-RX-API-DMAC7.html)
CN (1) CN102333530A (cg-RX-API-DMAC7.html)
AU (1) AU2010217605B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1007994A2 (cg-RX-API-DMAC7.html)
CA (1) CA2752003A1 (cg-RX-API-DMAC7.html)
ES (1) ES2411138T3 (cg-RX-API-DMAC7.html)
MX (1) MX2011008876A (cg-RX-API-DMAC7.html)
PL (1) PL2400960T3 (cg-RX-API-DMAC7.html)
PT (1) PT2400960E (cg-RX-API-DMAC7.html)
RU (1) RU2011138963A (cg-RX-API-DMAC7.html)
WO (1) WO2010097371A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2888634C (en) * 2012-10-19 2019-10-08 Ruth Perez Compositions and methods for the treatment of parkinson's disease
HK1212324A1 (en) * 2012-11-30 2016-06-10 株式会社爱茉莉太平洋 Novel pseudoceramide compound and production method for same
AU2014224237B2 (en) * 2013-03-05 2017-07-20 Biocon Limited A process for the preparation of 2-amino-1,3-propane diol compounds and salts thereof
KR101510683B1 (ko) 2013-09-03 2015-04-10 (주)네오팜 카나비노이드 수용체에 길항작용을 가지는 신규한 유사 세라마이드 유도체 및 이를 포함하는 약학 또는 화장품 조성물
EP3118621A1 (en) 2015-07-14 2017-01-18 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Methods and compositions for the diagnosis and for the treatment of adrenoleukodystrophy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0155015B1 (ko) * 1992-10-21 1998-12-01 고우야 마사시 2-아미노-1,3-프로판디올 화합물 및 면역 억제제
US5948820A (en) * 1994-08-22 1999-09-07 Yoshitomi Pharmaceutical Industries, Ltd. Benzene compound and pharmaceutical use thereof
DE69524962T4 (de) * 1994-08-22 2003-08-28 Mitsubishi Pharma Corp., Osaka Benzolderivate und deren medizinische verwendung
PL1773307T3 (pl) * 2004-07-30 2015-03-31 Novartis Ag Preparaty 2-amino-1,3-propanodioli i ich analogów
GT200600350A (es) * 2005-08-09 2007-03-28 Formulaciones líquidas
RU2433117C2 (ru) * 2005-12-15 2011-11-10 Мицубиси Танабе Фарма Корпорейшн Аминное соединение и его применение в медицинских целях
CN101240002B (zh) * 2007-02-07 2011-01-26 首都医科大学 脂肪酰氨基酰阿糖胞苷缀合物、其制备方法和应用

Also Published As

Publication number Publication date
RU2011138963A (ru) 2013-04-10
US20110306672A1 (en) 2011-12-15
ES2411138T3 (es) 2013-07-04
MX2011008876A (es) 2011-09-21
EP2400960B1 (en) 2013-04-17
PL2400960T3 (pl) 2013-08-30
EP2400960A1 (en) 2012-01-04
AU2010217605B2 (en) 2012-07-26
KR20110126631A (ko) 2011-11-23
AU2010217605A1 (en) 2011-08-18
JP2012518671A (ja) 2012-08-16
WO2010097371A1 (en) 2010-09-02
US8673982B2 (en) 2014-03-18
BRPI1007994A2 (pt) 2018-03-13
CN102333530A (zh) 2012-01-25
CA2752003A1 (en) 2010-09-02

Similar Documents

Publication Publication Date Title
US10442826B2 (en) Water-soluble acetaminophen analogs
US9415024B2 (en) Aminoalkanol derivatives
JP2019218356A (ja) カルビドパおよびl−ドーパプロドラッグならびにそれらの使用方法
ES2384324T3 (es) Derivados de aminopropanol como moduladores del receptor de esfingosina-1-fosfato
ES2411138T3 (es) Metabolitos análogos de ceramida
JPH0576939B2 (cg-RX-API-DMAC7.html)
NZ565696A (en) Liquid formulations comprising an S1P receptor modulator or agonist and propylene glycol
EP2504311A1 (en) Arachidonic acid analogs and methods for analgesic treatment using same
JPH0366670A (ja) 1,2,3,4―テトラヒドロ―9―アクリジナミンの誘導体
US20160317479A1 (en) Method of treating or preventing pain
EP0282127A2 (en) Beta-aminoethyl-substituted phenyl compounds, and anti-inflammatory or analgesic compositions containing them
RU2196130C2 (ru) Производные аминоэтилфеноксиуксусной кислоты и лекарственные средства для успокоения боли и облегчения отхождения камней при мочекаменной болезни
WO2011030205A1 (en) N-substituted benzenepropanamide or benzenepropenamide for use in the treatment of pain and inflammation
WO2011031911A1 (en) Deuterated alkyl phospholipid compounds, compositions, and methods of use
WO2005016331A1 (ja) N−(ベンゾイル)アミノ酸誘導体を有効成分とするニューロパシー性疼痛治療剤
JPH0714871B2 (ja) 筋弛緩剤
HK1093061B (en) Aminoalkanol derivatives
BR122020023057B1 (pt) Compostos de carbidopa e l-dopa, composições farmacêuticas compreendendo ditos compostos e uso das mesmas para tratar doença de parkinson ou para fornecer terapia de resgate a um indivíduo tendo doença de parkinson